13,191 research outputs found
Recommended from our members
UNDERSTANDING CONDITIONAL MODES OF ACTIONS IN CHEMICAL-INDUCED TOXICITY USING RULE MODELS
It is estimated that 115 million animals are used in experimental testing each year. Hence,
shifting efforts toward alternative methods for toxicity assessment is essential. However, slow regulatory acceptance of new approaches is governed by knowledge gaps in toxicity modes of action. In this thesis, I describe these challenges and the use of in vitro screening as an alternative of animal testing. I also discuss common data-based methods to derive hypotheses about toxicity modes of actions, and the associated limitations in capturing multiple biological perturbations.
I applied novel data-based workflows, using rule models, to prioritize in vitro assays predictive of toxicity as well as to detect significant polypharmacology profiles. I explain how constraints were applied to rule-based models to inform meaningful mechanistic interpretation for two toxicity endpoints: rat hepatotoxicity and acute toxicity. I compared assays selected, by rules, for predicting hepatotoxicity with endpoints used in in
vitro models from commercial sources. An overlap was observed including cytochrome
activity, mitochondrial toxicity and immunological responses. However, nuclear receptor
activity, identified in rules, is not currently covered in commercial setups. I also demonstrate that endocrine disruption endpoints extrapolate better into in vivo toxicity when a set of specific conditions are met, such as physicochemical properties associated with good bioavailability.
Next, I examined synergistic interactions between conditions in rules describing acute toxicity. I gained novel insights into how specific stressors potentiate the perturbation by known key events, such as acetylcholinesterase inhibition and neuro-signalling disruption. I show that examining polypharmacology profiles is particularly important at low bioactive potencies.
Further, the overall predictive performance of rules describing acute toxicity was tested against a benchmark Random Forest model in a conformal prediction framework. Irrespective to the data type used in the training, the models were prone to bias over compounds promiscuity, by which high promiscuous compounds were more likely to be predicted as toxic.
Overall, the studies conducted in this thesis provide novel insights into molecular mechanisms of toxicity, namely hepatotoxicity and acute toxicity, and with regards to chemical properties and polypharmacology. This knowledge can be used to improve the utility and design of alternative methods for toxicity, and hence, accelerate the regulatory acceptance.Islamic Development Bank
Cambridge Trust Fun
Transcriptomic responses of the olive fruit fly Bactrocera oleae and its symbiont Candidatus Erwinia dacicola to olive feeding
The olive fruit fly, Bactrocera oleae, is the most destructive pest of olive orchards worldwide. The monophagous larva has the unique capability of feeding on olive mesocarp, coping with high levels of phenolic compounds and utilizing non-hydrolyzed proteins present, particularly in the unripe, green olives. On the molecular level, the interaction between B. oleae and olives has not been investigated as yet. Nevertheless, it has been associated with the gut obligate symbiotic bacterium Candidatus Erwinia dacicola. Here, we used a B. oleae microarray to analyze the gene expression of larvae during their development in artificial diet, unripe (green) and ripe (black) olives. The expression profiles of Ca. E. dacicola were analyzed in parallel, using the Illumina platform. Several genes were found overexpressed in the olive fly larvae when feeding in green olives. Among these, a number of genes encoding detoxification and digestive enzymes, indicating a potential association with the ability of B. oleae to cope with green olives. In addition, a number of biological processes seem to be activated in Ca. E. dacicola during the development of larvae in olives, with the most notable being the activation of amino-acid metabolism
Multi-faceted Structure-Activity Relationship Analysis Using Graphical Representations
A core focus in medicinal chemistry is the interpretation of structure-activity relationships (SARs) of small molecules. SAR analysis is typically carried out on a case-by-case basis for compound sets that share activity against a given target. Although SAR investigations are not a priori dependent on computational approaches, limitations imposed by steady rise in activity information have necessitated the use of such methodologies. Moreover, understanding SARs in multi-target space is extremely difficult. Conceptually different computational approaches are reported in this thesis for graphical SAR analysis in single- as well as multi-target space. Activity landscape models are often used to describe the underlying SAR characteristics of compound sets. Theoretical activity landscapes that are reminiscent of topological maps intuitively represent distributions of pair-wise similarity and potency difference information as three-dimensional surfaces. These models provide easy access to identification of various SAR features. Therefore, such landscapes for actual data sets are generated and compared with graph-based representations. Existing graphical data structures are adapted to include mechanism of action information for receptor ligands to facilitate simultaneous SAR and mechanism-related analyses with the objective of identifying structural modifications responsible for switching molecular mechanisms of action. Typically, SAR analysis focuses on systematic pair-wise relationships of compound similarity and potency differences. Therefore, an approach is reported to calculate SAR feature probabilities on the basis of these pair-wise relationships for individual compounds in a ligand set. The consequent expansion of feature categories improves the analysis of local SAR environments. Graphical representations are designed to avoid a dependence on preconceived SAR models. Such representations are suitable for systematic large-scale SAR exploration. Methods for the navigation of SARs in multi-target space using simple and interpretable data structures are introduced. In summary, multi-faceted SAR analysis aided by computational means forms the primary objective of this dissertation
Analysis of Multitarget Activities and Assay Interference Characteristics of Pharmaceutically Relevant Compounds
The availability of large amounts of data in public repositories provide a useful source of knowledge in the field of drug discovery. Given the increasing sizes of compound databases and volumes of activity data, computational data mining can be used to study different characteristics and properties of compounds on a large scale. One of the major source of identification of new compounds in early phase of drug discovery is high-throughput screening where millions of compounds are tested against many targets. The screening data provides opportunities to assess activity profiles of compounds. This thesis aims at systematically mining activity data from publicly available sources in order to study the nature of growth of bioactive compounds, analyze multitarget activities and assay interference characteristics of pharmaceutically relevant compounds in context of polypharmacology. In the first study, growth of bioactive compounds against five major target families is monitored over time and compound-scaffold-CSK (cyclic skeleton) hierarchy is applied to investigate structural diversity of active compounds and topological diversity of their scaffolds. The next part of the thesis is based on the analysis of screening data. Initially, extensively assayed compounds are mined from the PubChem database and promiscuity of these compounds is assessed by taking assay frequencies into account. Next, DCM (dark chemical matter) or consistently inactive compounds that have been extensively tested are systematically extracted and their analog relationships with bioactive compounds are determined in order to derive target hypotheses for DCM. Further, PAINS (pan-assay interference compounds) are identified in the extensively tested set of compounds using substructure filters and their assay interference characteristics are studied. Finally, the limitations of PAINS filters are addressed using machine learning models that can distinguish between promiscuous and DCM PAINS. Structural context dependence of PAINS activities is studied by assessing predictions through feature weighting and mapping
Application and Development of Computational Methods for Ligand-Based Virtual Screening
The detection of novel active compounds that are able to modulate the biological function of a target is the primary goal of drug discovery. Different screening methods are available to identify hit compounds having the desired bioactivity in a large collection of molecules. As a computational method, virtual screening (VS) is used to search compound libraries in silico and identify those compounds that are likely to exhibit a specific activity. Ligand-based virtual screening (LBVS) is a subdiscipline that uses the information of one or more known active compounds in order to identify new hit compounds. Different LBVS methods exist, e.g. similarity searching and support vector machines (SVMs). In order to enable the application of these computational approaches, compounds have to be described numerically. Fingerprints derived from the two-dimensional compound structure, called 2D fingerprints, are among the most popular molecular descriptors available. This thesis covers the usage of 2D fingerprints in the context of LBVS. The first part focuses on a detailed analysis of 2D fingerprints. Their performance range against a wide range of pharmaceutical targets is globally estimated through fingerprint-based similarity searching. Additionally, mechanisms by which fingerprints are capable of detecting structurally diverse active compounds are identified. For this purpose, two different feature selection methods are applied to find those fingerprint features that are most relevant for the active compounds and distinguish them from other compounds. Then, 2D fingerprints are used in SVM calculations. The SVM methodology provides several opportunities to include additional information about the compounds in order to direct LBVS search calculations. In a first step, a variant of the SVM approach is applied to the multi-class prediction problem involving compounds that are active against several related targets. SVM linear combination is used to recover compounds with desired activity profiles and deprioritize compounds with other activities. Then, the SVM methodology is adopted for potency-directed VS. Compound potency is incorporated into the SVM approach through potencyoriented SVM linear combination and kernel function design to direct search calculations to the preferential detection of potent hit compounds. Next, SVM calculations are applied to address an intrinsic limitation of similarity-based methods, i.e., the presence of similar compounds having large differences in their potency. An especially designed SVM approach is introduced to predict compound pairs forming such activity cliffs. Finally, the impact of different training sets on the recall performance of SVM-based VS is analyzed and caveats are identified
Tau pathology in Alzheimer's disease and other dementias : translational approach from in vitro autoradiography to in vivo PET imaging
Tauopathies, including Alzheimer's disease (AD), corticobasal degeneration (CBD), and progressive supranuclear palsy (PSP), are complex neurodegenerative disorders characterized by the pathological accumulation of tau proteins in the brain. These often overlapping disorders, with intricate pathologies and growing prevalence, lack definitive treatments, highlighting the necessity for advanced research. Positron emission tomography (PET) imaging aids in the diagnosis and monitoring of diseases, by providing in vivo insights into pathological features. This thesis focused on deciphering the binding properties and brain regional distribution of PET tracers for accurate disease differentiation. Spanning four studies, we aimed to bridge in vitro and in vivo PET data to investigate tau pathology and its association with dementia-related markers such as reactive astrogliosis, peripheral inflammation, and dopaminergic dysfunction. The 2nd generation tau PET tracers, 3H-MK6240 and 3H-PI2620, demonstrated high affinity and specificity in AD post-mortem brain tissues, especially in early-onset AD, compared to controls. 3H-PI2620, 3H-MK6240, and 3HRO948 displayed similar binding patterns in AD tissue, with multiple binding sites and equivalent high affinities (Papers I and II). 3H-PI2620 showed specificity in CBD and PSP tissues, in contrast to 3H-MK6240. However, differentiating CBD from PSP brains with 3H-PI2620 remained challenging in multiple brain regions, potentially due to complex tracer-target interactions (Papers II and III). Reactive astrogliosis PET tracers 3H-Deprenyl and 3H-BU99008 bound primarily to stable distinct high-affinity binding sites in AD, CBD and PSP, but also to transient binding sites, differing by brain region and condition. This pattern implied that these tracers may interact with similar or diverse subtypes or populations of astrocytes, expressing varying ratios of transient sites, which may vary depending on the brain location and the disease (Paper III). Using 3H-FEPE2I, we delineated a reduction in dopamine transporter (DAT) levels within the putamen across CBD, PSP and Parkinson's Disease (PD) brains. Concomitantly, elevated 3H-Raclopride binding reflected higher dopamine D2 receptor (D2R) levels in PSP and PD. Nonetheless, our observations underscored the heterogeneity inherent to these neurodegenerative pathologies, emphasizing the criticality of individual variability in neuropathological manifestations (Paper III). Lastly, we investigated late middle-aged cognitively unimpaired Hispanic individuals, in dichotomous groups of in vivo amyloid-β (Aβ) PET (18F-Florbetaben) and plasma neurofilament light (NfL) biomarkers. Our findings suggest that elevated plasma inflammation and tau burden as measured by 18FMK6240, can be detected at early preclinical stages of AD, offering potential for early diagnosis (Paper IV). This thesis underscored the importance of PET imaging in advancing our understanding of tauopathies. The innovative use of multiple PET tracers provided crucial insights into their potential use in clinics to distinguish pathological features of AD, CBD and PSP. The findings emphasized the need for more studies applying a multifaceted approach to studying and managing these complex neurodegenerative disorders, combining advanced imaging techniques with a broad spectrum of biological markers
Recommended from our members
Computational advances in combating colloidal aggregation in drug discovery.
Small molecule effectors are essential for drug discovery. Specific molecular recognition, reversible binding and dose-dependency are usually key requirements to ensure utility of a novel chemical entity. However, artefactual frequent-hitter and assay interference compounds may divert lead optimization and screening programmes towards attrition-prone chemical matter. Colloidal aggregates are the prime source of false positive readouts, either through protein sequestration or protein-scaffold mimicry. Nevertheless, assessment of colloidal aggregation remains somewhat overlooked and under-appreciated. In this Review, we discuss the impact of aggregation in drug discovery by analysing select examples from the literature and publicly-available datasets. We also examine and comment on technologies used to experimentally identify these potentially problematic entities. We focus on evidence-based computational filters and machine learning algorithms that may be swiftly deployed to flag chemical matter and mitigate the impact of aggregates in discovery programmes. We highlight the tools that can be used to scrutinize libraries, and identify and eliminate these problematic compounds.D.R. is a Swiss National Science Foundation Fellow (Grants P2EZP3_168827 and P300P2_177833). G.J.L.B. is a Royal Society URF (UF110046 and URF/R/180019), an iFCT Investigator (IF/00624/2015), and the recipient of an ERC StG (TagIt, Grant Agreement 676832). T.R. and G.J.L.B. acknowledge Marie Sklodowska-Curie ITN Protein Conjugates (Grant Agreement 675007) for funding. T.R. is a Marie Curie Fellow (Grant Agreement 743640). T.R. acknowledges the H2020 (TWINN-2017 ACORN, Grant Agreement 807281) and POR Lisboa 2020/FEDER (02/SAICT/2017, Grant Agreement Lisboa-01-0145-FEDER-028333) for funding. D.R. acknowledges the MIT-IBM Watson AI Lab and the MIT SenseTime coalition for funding
- …